Oncolytics Biotech (NASDAQ:ONCY) Upgraded to “Moderate Buy” at Raymond James
Raymond James upgraded shares of Oncolytics Biotech (NASDAQ:ONCY – Free Report) to a moderate buy rating in a research report released on Thursday morning,Zacks.com reports. Raymond James also issued estimates for Oncolytics Biotech’s Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.32) EPS, Q1 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.34) […]
More Stories
Ipswich Investment Management Co. Inc. Sells 150 Shares of General Electric (NYSE:GE)
Ipswich Investment Management Co. Inc. reduced its stake in shares of General Electric (NYSE:GE – Free Report) by 1.6% in...
Archer Investment Corp Increases Stock Position in Automatic Data Processing, Inc. (NASDAQ:ADP)
Archer Investment Corp grew its position in shares of Automatic Data Processing, Inc. (NASDAQ:ADP – Free Report) by 5.4% during...
1776 Wealth LLC Sells 198 Shares of Salesforce, Inc. (NYSE:CRM)
1776 Wealth LLC cut its holdings in shares of Salesforce, Inc. (NYSE:CRM – Free Report) by 2.9% in the 3rd...
Philip Morris International Inc. (NYSE:PM) Stake Lessened by Cutler Investment Counsel LLC
Cutler Investment Counsel LLC decreased its holdings in shares of Philip Morris International Inc. (NYSE:PM – Free Report) by 9.6%...
The Walt Disney Company (NYSE:DIS) Shares Purchased by Natixis Advisors LLC
Natixis Advisors LLC boosted its stake in shares of The Walt Disney Company (NYSE:DIS – Free Report) by 3.1% in...
AbbVie (NYSE:ABBV) Now Covered by Analysts at Wolfe Research
Wolfe Research initiated coverage on shares of AbbVie (NYSE:ABBV – Free Report) in a report published on Friday, Marketbeat.com reports....